

Disclosures

Personal Commercial (21)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott Laboratories	Other - Event Adjudication Committee	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Abbvie	Data Safety Monitoring Board	Significant (>= \$5,000)	Other
Arena	Data Safety Monitoring Board	Modest (< \$5,000)	Other
AstraZeneca	Research/Research Grants	Significant (>= \$5,000)	Other General Cardiology
Bayer	Consultant Fees/Honoraria	Significant (>= \$5,000)	Other
Boehringer Ingelheim	Consultant Fees/Honoraria	Significant (>= \$5,000)	Other
Boehringer Ingelheim	Research/Research Grants	Significant (>= \$5,000)	Other
CSL Behring	Data Safety Monitoring Board	Modest (< \$5,000)	Other
CSL Behring	Data Safety Monitoring Board	Modest (< \$5,000)	General Cardiology
Eidos	Data Safety Monitoring Board	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Esperion	Research/Research Grants	Modest (< \$5,000)	Prevention
GlaxoSmithKline	Consultant Fees/Honoraria	Significant (>= \$5,000)	Other
Lilly US	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
Lilly USA	Research/Research Grants	Significant (>= \$5,000)	Prevention
Merck	Research/Research Grants	Modest (< \$5,000)	Other
Merck	Consultant Fees/Honoraria	Modest (< \$5,000)	Other
Novo Nordisk Inc.	Research/Research Grants	Significant (>= \$5,000)	General Cardiology
Novo Nordisk Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
Otsuka Pharmaceutical Co.	Data Safety Monitoring Board	Modest (< \$5,000)	Other
Pfizer Inc	Consultant Fees/Honoraria	None (\$0)	Other
Ventyx	Data Safety Monitoring Board	Modest (< \$5,000)	Other

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2021	empagliflozin patent	Defendant † Kirkland Ellis FBO Boehringer Ingelheim	patent lawsuit	Significant (>= \$5,000)

Agreement

Certified Education Attestation | Signed on 9/13/2022
URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/13/2022
URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 9/13/2022
URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 9/13/2022

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.